Aspirin and hemocompatibility related adverse events after LVAD implantation in patients with diabetes mellitus, obesity and atrial fibrillation: the ARIES-HM3 randomized clinical trial

2 September 2024 (15:27 - 15:39)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Doctor Nir Uriel

Columbia University, New York (United States of America)

4 More presentations in this session

Presentation thumbnail

Long-acting Factor XI Inhibition and Periprocedural Bleeding: A Secondary Analysis from AZALEA-TIMI 71

Doctor S. Patel (Boston, US)

Presentation thumbnail

Efficacy and safety of anticoagulation in patients with device-detected atrial fibrillation by indication for acetylsalicylic acid therapy

Professor R. Schnabel (Hamburg, DE)

Presentation thumbnail

The Association between Age and Clinical Outcomes in Patients with Subclinical Atrial Fibrillation Treated with Apixaban: Insights from the ARTESiA Trial

Associate Professor M. Proietti (Milan, IT)

Presentation thumbnail

Changes in Cognitive Function in Patients with Subclinical Atrial Fibrillation Treated with Apixaban or Aspirin: A Sub-Study from the ARTESiA Trial

Doctor L. Rivard (Montreal, CA)

Access the full session

Session thumbnail

Smaller trials, trial updates, and other studies on antiplatelet and antithrombotic therapies

The Event

Event poster

ESC Congress 2024

2 September 2024 15:27 CET

You may be interested in

Congress Presentation

Outcomes with aspirin avoidance after implantation of a Fully Magnetically Levitated LVAD in patients with coronary, cerebral or peripheral vascular disease: the ARIES HM3 randomized clinical trial

Congress Presentation

Reducing residual risk in left ventricular assist device carriers: lessons from ARIES-HM3 trial

Congress Session

Smaller trials, trial updates, and other studies on antiplatelet and antithrombotic therapies

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources